Prevalence and factors associated with nonalcoholic fatty liver disease in a nonobese Korean population

Gut and Liver

Volumn 10, Issue 1, 2016, Pages 117-125

  Cho, Hyun Chin ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

Author keywords

Non alcoholic fatty liver disease; Nonobese population

Indexed keywords

ALANINE AMINOTRANSFERASE; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HYPERURICEMIA; KOREAN (PEOPLE); MALE; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; WAIST CIRCUMFERENCE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; COMPLICATION; HOMEOSTASIS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR; SEX DIFFERENCE; SOUTH KOREA; STATISTICS AND NUMERICAL DATA;

ADULT; ALANINE TRANSAMINASE; ANTHROPOMETRY; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; HOMEOSTASIS; HUMANS; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INSULIN RESISTANCE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PREVALENCE; REPUBLIC OF KOREA; RISK FACTORS; SEX FACTORS; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84957310599     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl14444     Document Type: Article

References (47)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346:1221-1231.
2. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003;38: 954-961.
3. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepati-tis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-1219.
4. Farrell GC, Chitturi S, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007;22:775-777.
5. Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010;51:1593-1602.
6. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010;28:155-161.
7. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395.
8. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellen-tani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42:44-52.
9. Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastro-enterol Hepatol 2006;21:138-143.
10. Kim HJ, Kim HJ, Lee KE, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004;164:2169-2175.
11. Chen CH, Huang MH, Yang JC, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006;40:745-752.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
13. Needleman L, Kurtz AB, Rifkin MD, Cooper HS, Pasto ME, Goldberg BB. Sonography of diffuse benign liver disease: accuracy of pattern recognition and grading. AJR Am J Roentgenol 1986;146: 1011-1015.
14. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-163.
15. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285: 2486-2497.
17. Sullivan GM, Feinn R. Using effect size-or why the p value is not enough. J Grad Med Educ 2012;4:279-282.
18. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol 2013;108:1299-1304.
19. Kim NH, Kim JH, Kim YJ, et al. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver Int 2014;34:604-611.
20. Bhat G, Baba CS, Pandey A, Kumari N, Choudhuri G. Insulin resistance and metabolic syndrome in nonobese Indian patients with non-alcoholic fatty liver disease. Trop Gastroenterol 2013;34:18-24.
21. Vendhan R, Amutha A, Anjana RM, Unnikrishnan R, Deepa M, Mohan V. Comparison of characteristics between nonobese and overweight/obese subjects with nonalcoholic fatty liver disease in a South Indian population. Diabetes Technol Ther 2014;16:48-55.
22. Tsuneto A, Hida A, Sera N, et al. Fatty liver incidence and predictive variables. Hypertens Res 2010;33:638-643.
23. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012;142:711-725.
24. Speliotes EK, Massaro JM, Hoffmann U, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010;51:1979-1987.
25. Sinn DH, Gwak GY, Park HN, et al. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am J Gastroenterol 2012;107: 561-567.
26. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 2009;50:1029-1034.
27. Lee JW, Cho YK, Ryan M, et al. Serum uric acid as a predictor for the development of nonalcoholic fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut Liver 2010;4:378-383.
28. Xu C, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study. PLoS One 2010;5:e11578.
29. Hwang IC, Suh SY, Suh AR, Ahn HY. The relationship between normal serum uric acid and nonalcoholic fatty liver disease. J Korean Med Sci 2011;26:386-391.
30. Liu PW, Chang TY, Chen JD. Serum uric acid and metabolic syndrome in Taiwanese adults. Metabolism 2010;59:802-807.
31. Godsland IF, Lecamwasam K, Johnston DG. A systematic evaluation of the insulin resistance syndrome as an independent risk factor for cardiovascular disease mortality and derivation of a clinical index. Metabolism 2011;60:1442-1448.
32. Albano E, Mottaran E, Occhino G, Reale E, Vidali M. Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther 2005;22 Suppl 2:71-73.
33. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000;148:131-139.
34. Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 2001;38:365-371.
35. Garcia-Ruiz I, Rodriguez-Juan C, Diaz-Sanjuan T, et al. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology 2006;44:581-591.
36. Hayden MR, Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab (Lond) 2004;1:10.
37. Suzuki I, Yamauchi T, Onuma M, Nozaki S. Allopurinol, an inhibitor of uric acid synthesis: can it be used for the treatment of metabolic syndrome and related disorders? Drugs Today (Barc) 2009;45:363-378.
38. Sanchez-Lozada LG, Mu W, Roncal C, et al. Comparison of free fructose and glucose to sucrose in the ability to cause fatty liver. Eur J Nutr 2010;49:1-9.
39. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-1123.
40. Sonsuz A, Basaranoglu M, Ozbay G. Relationship between amino-transferase levels and histopathological findings in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000;95:1370-1371.
41. Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord 2004;28: 167-172.
42. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol 2007;46:700-707.
43. Nelson JE, Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 2011;53:448-457.
44. Imeryuz N, Tahan V, Sonsuz A, et al. Iron preloading aggravates nutritional steatohepatitis in rats by increasing apoptotic cell death. J Hepatol 2007;47:851-859.
45. Choi JS, Koh IU, Lee HJ, Kim WH, Song J. Effects of excess dietary iron and fat on glucose and lipid metabolism. J Nutr Biochem 2013;24:1634-1644.
46. Dongiovanni P, Ruscica M, Rametta R, et al. Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol 2013;182:2254-2263.
47. Choi ES, Kim MK, Song MK, et al. Association between serum irisin levels and non-alcoholic fatty liver disease in health screen examinees. PLoS One 2014;9:e110680.